headphotoAssociate Professor

Ph.D.

Tel:   39431100

Email:   This email address is being protected from spambots. You need JavaScript enabled to view it.

Address:

  508A, Lo Kwee-Seong Integrated Biomedical Sciences Building, Area 39, CUHK

 

 

Biography

Prof. CHEN Yangchao (陳揚超) is currently an Associate Professor at School of Biomedical Sciences, The Chinese University of Hong Kong (CUHK). He obtained his Ph.D. from Sun Yat-sen University in 2003 and later on was trained as a postdoctoral fellow at University of Washington, Seattle. He has been faculty member as Research Assistant Professor, Assistant Professor and Associate Professor at Faculty of Medicine CUHK since 2007. His research interests include epigenetics in cancer, histone modification particularly methylation, long and short non-coding RNAs, development of novel therapeutics for liver and pancreatic cancer. The ultimate goal of his lab is aimed at the identification of novel diagnostic markers and therapeutic targets for pancreatic and liver cancer.

  1. Identification of novel diagnostic markers and therapeutic targets for digestive cancers including pancreatic cancer and liver cancer
  2. Identification and characterization of long and short non-coding RNAs with critic roles in cancer
  3. Identification of cancer associated genes using large scale genetic perturbation screen such as CRISPR/CAS9
  4. Functional roles of EZH2 in cancer
  5. Development of novel therapeutics for cancer
  1. Xu, F., Li, C.H., Wong, C.H., Chen, G.G., Lai, P.B.S., Shao, S., Chan, S.L., Chen, Y. (2019). Genome-wide screening and functional analysis identifies tumor suppressor long non-coding RNAs epigenetically silenced in hepatocellular carcinoma. Cancer Res., pii: canres.1659.2018. doi: 10.1158/0008-5472.CAN-18-1659. [Epub ahead of print].
  2. Wong, C.H., Chen, Y. (2019). Clinical significance of exosomes as potential biomarkers in cancer. World J Clin Cases, 7(2), 171-190.
  3. Li, C.H., Tang, S.C., Wong, C.H., Wang, Y., Jiang, J.D., Chen, Y. (2018). Berberine induces miR-373 expression in hepatocytes to inactivate hepatic steatosis associated AKT-S6 kinase pathway. Eur. J. Pharmacol., 825, 107-118.
  4. Xiao, Z., Chen, Y. (2017). Identification of Small Molecule Modulators of MicroRNA by Library Screening. Methods Mol. Biol., 1517, 169-178.
  5. Li, C.H., Xiao, Z., Tong, J., To, K.F., Fang, X., Cheng, A.S.L. & Chen, Y. (2017). EZH2 Coupled with HOTAIR to Silence MicroRNA-34a by the induction of heterochromatin formation in Human Pancreatic Ductal Adenocarcinoma. Int. J. Cancer, 140, 120-129.
  6. Lau, O.C., Shen, B., Wong, C.O., Tjong, Y.W., Lo, C.Y., Wang, H.C., Huang, Y., Yung, W.H. & Chen, Y., Fung, M.L., Rudd, J.A. & Yao, X. (2016). TRPC5 channels participate in pressure-sensing in aortic baroreceptors. Nat. Commun., 7, 11947.
  7. Li, C.H. & Chen, Y. (2015). Small and Long Non-Coding RNAs: Novel Targets in Perspective Cancer Therapy. Current Genomics, 16, 319-326.
  8. Xiao, Z., Li, C.H., Chan, S.L., Xu, F., Feng, L., Wang, Y., Jiang, J.D., Sung, J.J.Y., Cheng, C.H.K. & Chen, Y. (2014). A small molecule modulator of the tumor suppressor miRNA-34a inhibits the growth of hepatocellular carcinoma. Cancer Res., 74(21), 6236-6247.
  9. Li, C.H., Xu, F., Chow, S.C., Feng, L., Yin, D., Ng, T.B. & Chen, Y. (2014). Hepatitis B virus X protein promotes hepatocellular carcinoma transformation through interlukin-6 activation of microRNA-21 expression. Eur. J. Cancer, 50, 2560-2569.
  10. He, C.Y., Fu, J., Ma, J.Y., Feng, R., Tan, X.S., Huang, M., Shou, J.W., Zhao, Z.X., Li, X.Y., Zhang, X.F. & Chen, Y., Wang, Y. (2014). Biotransformation and metabolic profile of extracts with potential anti-tumor activity from a traditional Miao-nationality herbal medicine, Polygonum capitatum in vitro. Molecules, 19(7),10291-10308.
  11. Tang, S.C. & Chen, Y. (2014). Novel Therapeutic Targets for Pancreatic Cancer. World J. Gastroenterol., 20, 10825-10844.
  12. Xiao, Z.G., Chow, S.C., Li, C.H., Tang, S.C., Tsui, S.K.W., Lin, Z.X. & Chen, Y. (2014). Role of microRNA-95 in the anticancer activity of Brucein D in hepatocellular carcinoma. Eur. J. Pharmacol., 728, 141-150.
  13. Li, C.H. & Chen, Y. (2013). Targeting long non-coding RNAs in cancer: progress and perspective. Int. J. Biochem. Cell Biol., 45, 1895-1910.
  14. Li, C.H., To, K.F., Tong, J.H., Xiao, Z., Xia, T., Lai, P.B., Chow, S.C., Zhu, Y.X., Chan, S.L., Marquez, V.E. & Chen, Y. (2013). Enhancer of Zeste Homolog 2 Silences microRNA-218 in Human Pancreatic Ductal Adenocarcinoma Cells by Inducing Formation of Heterochromatin. Gastroenterology, 144, 1086-1097.
  15. Cheng, A.S.L., Lau, S.S., Chen, Y., Kondo, Y., Li, M.S., Feng, H., Ching, A.K., Cheung, P.K., Wong, K.H., Jin, H., Choy, R., Yu, J., To, K.F., Wong, N., Huang, T.H. & Sung, J.J.Y. (2011). EZH2–mediated concordant repression of Wnt antagonists promotes β- catenin –dependent hepatocarcinogenesisi. Cancer Res., 71, 4028-4039.
  16. Wong, W.T., Tian, X.Y., Chen, Y., Leung, F.P., Wong, S.L., Lee, H.K., Ng, C.F., Yao, X., Vanhoutte, Tipoe G. & Huang, Y. (2010). COX-2 up-regulation and prostaglandin F2α mediate bone morphogenic protein 4-induced endothelial dysfunction in hypertension. Circ. Res., 107, 984-991.
  17. Chen, Y., Lin, M.C., Yao, H., Wang, H., Zhang, A.Q., Yu, J., Hui, C.K., Lau, G.K., He, M.L., Sung, J. & Kung, H.F. (2007). Lentivirus-mediated RNA interference targeting enhancer of zeste homolog 2 inhibits hepatocellular carcinoma growth through down-regulation of stathmin. Hepatology, 46, 200-208
  18. Chen, Y., Lin, M.C., Wang, H., Chan, C.Y., Jiang, L., Ngai, S.M., Yu, J., He, M.L., Shaw, P.C., Yew, D.T., Sung, J.J. & Kung, H.F. (2007). Proteomic analysis of EZH2 downstream target proteins in hepatocellular carcinoma. Proteomics, 7, 3097-3104.
  19. Chen, Y., Stamatoyannopoulos G & Song CZ. (2003). Down-regulation of CXCR4 by inducible expression of siRNAs inhibited breast cancer cell invasion in vitro. Cancer Res., 63, 4801-4804.
  20. Song, C.Z., Keller, K. Chen, Y. & Stamatoyannopoulos, G. (2003). Functional interplay between CBP and PCAF in acetylation and regulation of transcription factor KLF13 activity, J. Mol. Biol., 329, 207-215.
  1. Coming soon